Pharmicell Co: Q3 2024 revenue dropped 22.8% YoY to ₩43.4B, with net income at ₩2.18B

About this update from Pharmicell Co., Ltd

Q3 2024 revenue fell 22.8% YoY to ₩43.4B, with net income at ₩2.18B. Bio-Chemical led sales, while Bio-Medical posted losses. R&D investment remains high, and the company is expanding production capacity for nucleosides and mPEG amid strong biotech demand.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmicell Co., Ltd